National: Syrup of Sorrow: Kids’ Cure or Killer?
Shadows Over Chhindwara
In the dusty lanes of Chhindwara district, Madhya Pradesh, a routine sniffle turned deadly for dozens of young lives. Starting late August 2025, parents sought quick relief for their children’s coughs and fevers, turning to a familiar pink bottle: Coldrif cough syrup.
What they handed over as comfort soon revealed itself as poison. By early October, the toll climbed to 20 children gone, mostly under five, their tiny kidneys overwhelmed by a hidden toxin. Families in Parasia and nearby blocks now whisper of betrayal, where medicine promised healing but delivered heartbreak.
The Hidden Toxin
Lab tests cut through the initial confusion like a scalpel. Samples from Tamil Nadu’s drug authority detected 48.6 percent diethylene glycol, or DEG, in Coldrif batches, far beyond the safe limit of 0.1 percent set by Indian regulators and the World Health Organization.
This industrial solvent, cheap and sweet-tasting, sneaks into formulations as a cost-cutting diluent. Once ingested, it ravages organs, mimicking a cold’s chill before sparking acute kidney failure. In Madhya Pradesh’s own labs, levels hit 46.28 percent, confirming the adulteration that stole breaths from playground dreams.
Echoes in Rajasthan’s Heartland
The crisis spilled across borders into Rajasthan, where two more young souls fell in Bharatpur and Sikar. These cases tied back to syrups under the state’s free medicine scheme, including a dextromethorphan variant unsafe for toddlers.
Parents there recall hurried clinic visits, prescriptions scribbled without a second glance. One mother in Sikar watched her five-year-old seize and fade hours after a dose, her pleas for tests met with shrugs. Now, four deaths nationwide bear this mark, a stark reminder that borders mean little to grief.
Hands Held Accountable
Police moved decisively, arresting G Ranganathan, owner of Sresan Pharmaceutical Manufacturer in Kanchipuram, Tamil Nadu, on October 9. Charges of culpable homicide loomed over the firm, whose factory supplied the tainted lots to Madhya Pradesh and beyond.
A government doctor in Chhindwara faced detention too, accused of prescribing the syrup to multiple victims despite its risks. Raids sealed godowns of distributors like Kataria Pharmaceuticals in Jabalpur, while pharmacies across districts surrendered bottles for scrutiny.
- Key Figures in Custody:
- G Ranganathan, Sresan Pharma owner
- Unnamed Chhindwara pediatrician
- Several pharmacy staff for stocking banned stock
Waves of Bans and Warnings
Madhya Pradesh led the clampdown on October 4, prohibiting Coldrif and all Sresan products statewide. Tamil Nadu followed suit, halting sales from October 1 after their tests flagged the danger.
Rajasthan suspended its drug controller, Rajaram Sharma, and paused distribution from Kaysons Pharma, whose 42 substandard samples since 2012 raised red flags. Kerala and Uttar Pradesh joined the fray, banning the syrup amid fears of wider spread. The Union Health Ministry’s advisory rang clear: no cough remedies for children under two, urging honey and rest instead.
Families in the Quiet Aftermath
Shivani Thakre sits in her Parasia home, surrounded by her lost child’s toys and a faded photo. The 24-year-old’s voice cracks as she recounts the doctor’s nod to Coldrif for her toddler’s flu. “We trusted the bottle’s label,” she says, fingers tracing empty sleeves.
Across Chhindwara, vigils flicker with candles and questions. Grieving kin reject compensation offers, demanding trials that name every link in the chain. Five children linger in intensive care, their recoveries a fragile thread pulling at parental hopes.
Outrage Fuels National Reckoning
Public fury boiled over on social platforms, with parents and activists decrying a system that lets toxins slip through. Congress leader Sachin Pilot pushed for a judicial probe in Rajasthan, slamming state probes as too cozy. Shiv Sena’s mouthpiece Saamana called for homicide charges, echoing calls from the National Human Rights Commission.
The NHRC fired notices to Madhya Pradesh, Rajasthan, and Uttar Pradesh governments, tasking the Drugs Controller General of India with a supply chain audit. Even the World Health Organization voiced concerns, probing export risks from India’s pharma hubs. Protests swelled in Lucknow and Jaipur, parents marching with placards that read, “Not a cold, but a crime.”
A System’s Fractured Trust
This scandal revives ghosts of 2022’s global cough syrup tragedies, where over 300 children perished from similar lapses. Experts spotlight weak testing labs, understaffed inspectors, and a reliance on unverified generics that prioritize price over purity.
Yet glimmers emerge: the Centre’s high-level meet on October 5 rallied states for better surveillance via the Integrated Disease Surveillance Programme. Rational prescribing campaigns now flood clinics, teaching that most kid coughs fade without a drop. As investigations deepen, the real test lies in rebuilding faith, one safe bottle at a time.
Glimmers of Guarded Hope
In the shadow of loss, small steps stir. Community health workers in Chhindwara now fan out with leaflets on spotting fakes via smartphone scanners, checking batch codes against official registries. Schools weave in lessons on medicine myths, turning tragedy into quiet armor.
For the families, healing inches forward through shared stories in village squares. The fight, they say, honors the little ones by shielding the next. Until every syrup sings true, vigilance remains their vigil.